Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ovid Therapeutics (OVID) Accounts Payables (2016 - 2026)

Ovid Therapeutics filings provide 11 years of Accounts Payables readings, the most recent being $8.9 million for Q1 2026.

  • Quarterly Accounts Payables rose 355.18% to $8.9 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $8.9 million through Mar 2026, up 355.18% year-over-year, with the annual reading at $2.0 million for FY2025, 38.72% down from the prior year.
  • Accounts Payables hit $8.9 million in Q1 2026 for Ovid Therapeutics, up from $2.0 million in the prior quarter.
  • Across five years, Accounts Payables topped out at $8.9 million in Q1 2026 and bottomed at $1.0 million in Q3 2022.
  • Average Accounts Payables over 5 years is $3.1 million, with a median of $2.7 million recorded in 2024.
  • Peak annual rise in Accounts Payables hit 407.58% in 2022, while the deepest fall reached 72.6% in 2022.
  • Ovid Therapeutics' Accounts Payables stood at $2.0 million in 2022, then soared by 89.61% to $3.7 million in 2023, then dropped by 13.8% to $3.2 million in 2024, then tumbled by 38.72% to $2.0 million in 2025, then skyrocketed by 353.78% to $8.9 million in 2026.
  • Per Business Quant, the three most recent readings for OVID's Accounts Payables are $8.9 million (Q1 2026), $2.0 million (Q4 2025), and $1.7 million (Q3 2025).